Stuart Therapeutics, Inc.
PrivateLast Round
Series A
Mar 19, 2021
Total Funding Raised
$11M
Company Overview
Stuart Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops a synthesized peptide therapeutic platform intended to repair disease-damaged helical collagen in the eye.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Stuart Therapeutics, Inc. Comparables
Compare Stuart Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TearSolutions | 87% | |
| Selagine, Inc. | 81% | |
| Aldeyra Therapeutics | 81% |
Stuart Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 19, 2021 |
Key People
Founding team and executive leadership
Stuart Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioBrit | Series A |
| Wisconsin Alumni Research Foundation | Series A |
| InFocus Capital Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors increased 46% MoM.
- May 2, 2025
Monthly visitors increased 32% MoM, reaching 1.3K.
Recent news
Latest coverage and updates
- hiresAug 26, 2026
Stuart Therapeutics, Inc. hired Dave LeCause as senior commercial advisor on Aug 26th '26.
- hiresAug 19, 2026
Stuart Therapeutics, Inc. hired David Jakeman as chief financial officer on Aug 18th '26.
Stuart Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Stuart Therapeutics, Inc.'s valuation, stock price, and market status.
Is Stuart Therapeutics, Inc. a public or private company?
Stuart Therapeutics, Inc. is a private company.
What is the current stock price of Stuart Therapeutics, Inc.?
Stuart Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Stuart Therapeutics, Inc. worth (valuation)?
Valuation information for Stuart Therapeutics, Inc. is not publicly available.
Can I buy Stuart Therapeutics, Inc. stock?
Stuart Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Stuart Therapeutics, Inc.'s last funding round?
Stuart Therapeutics, Inc.'s most recent funding round was Series A on March 19, 2021.
Who are the main investors in Stuart Therapeutics, Inc.?
Key investors in Stuart Therapeutics, Inc. include InFocus Capital Partners.
Will Stuart Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Stuart Therapeutics, Inc..
How can I track Stuart Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Stuart Therapeutics, Inc.'s secondary market activity and sign up for updates.